Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Long Interval Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Behavioral Memory Modulation in Nicotine Addiction

NCT03744559
View directory record Official record
Conditions
Nicotine Use Disorder
Interventions
Retrieval Extinction Training (RET), Control Retrieval Extinction Training (RET)
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
25 Years to 65 Years
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 5, 2026, 2:17 AM EDT
Completed Not applicable Interventional

Impact of Automated Education and Follow-up Mechanisms on Patient Engagement

NCT02279901
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Telemedicine Education, IVR
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
1,873 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Fontana, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 5, 2026, 2:17 AM EDT
Completed Not applicable Interventional

Testing a Secondary Prevention Intervention for HIV-Positive Black Young Men Who Have Sex With Men

NCT01751594
View directory record Official record
Conditions
HIV, AIDS
Interventions
MOVE Intervention, H4L Comparison Intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years · Male only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 5, 2026, 2:17 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

HIIT vs. MICT Training Study

NCT05513300
View directory record Official record
Conditions
Lifestyle, Sedentary
Interventions
Exercise intervention
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 5, 2026, 2:17 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Feasibility and Efficacy of rTMS in Healthy Persons

NCT04074811
View directory record Official record
Conditions
Executive Dysfunction, Pain, Mood
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Wayne State University
Other
Eligibility
21 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 5, 2026, 2:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

High-risk Obstetrical Patient Intervention Utilizing the Contraceptive CHOICE Project Script

NCT03049592
View directory record Official record
Conditions
Diabetes, Contraception
Interventions
HIBISCUS counseling
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Sep 5, 2026, 2:17 AM EDT
Not listed Phase 4 Interventional

Novel Form of Acquired Long QT Syndrome

NCT04169100
View directory record Official record
Conditions
Long QT Syndrome, Connective Tissue Diseases, Rheumatoid Arthritis
Interventions
Prednisone
Drug
Lead sponsor
Narrows Institute for Biomedical Research
Other
Eligibility
18 Years to 89 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Sep 5, 2026, 2:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Long-Working Distance OCT for Children

NCT02582164
View directory record Official record
Conditions
Retinal Diseases, Optic Nerve Diseases
Interventions
Duke Biomedical Engineering's Long-working distance OCT
Device
Lead sponsor
Duke University
Other
Eligibility
6 Months and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Sep 5, 2026, 2:17 AM EDT
Recruiting Phase 3 Interventional

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

NCT06663332
View directory record Official record
Conditions
Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
Interventions
Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
5
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 5, 2026, 2:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Time-Restricted Eating and Mindfulness-Based Stress Reduction to Reduce the Risk of Early-Onset Colorectal Cancer

NCT06022887
View directory record Official record
Conditions
Obesity, Colorectal Cancer, Microbial Colonization, Time Restricted Feeding, Stress, Psychological
Interventions
TRE, MBSR
Behavioral
Lead sponsor
Lisa Tussing-Humphreys
Other
Eligibility
18 Years to 39 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 5, 2026, 2:17 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

NCT07120503
View directory record Official record
Conditions
Asthma (Diagnosis)
Interventions
WIN378, Placebo
Drug
Lead sponsor
Windward Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Los Angeles, California • San Jose, California • Melbourne, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 5, 2026, 2:17 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

NCT06741397
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA, New formulation of CAB LA
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 5, 2026, 2:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas

NCT00766753
View directory record Official record
Conditions
Malignant Glioma
Interventions
Dendritic vaccine pulsed with multiple peptides, The first booster vaccine phase:, The second booster vaccine phase:
Biological
Lead sponsor
Frank Lieberman
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 5, 2026, 2:17 AM EDT
Recruiting Phase 1 Interventional

A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

NCT02852213
View directory record Official record
Conditions
AADC Deficiency
Interventions
AAV2-hAADC
Drug
Lead sponsor
Krzysztof Bankiewicz
Other
Eligibility
24 Months and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2037
U.S. locations
3
States / cities
San Francisco, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 5, 2026, 2:17 AM EDT
Completed Phase 1 Interventional

A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder

NCT03854409
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Little Rock, Arkansas • Garden Grove, California • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 5, 2026, 2:17 AM EDT
Completed Not applicable Interventional Results available

Foley Catheter Compared to the Foley Catheter Alone for Cervical Ripening

NCT03111316
View directory record Official record
Conditions
Cervical Ripening, Induction of Labor
Interventions
Cervidil 10 MG Vaginal Insert, Foley Catheter
Drug · Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 5, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

NCT01175213
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety), SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety), IV treatment with IGSC, 10%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
2 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Cypress, California • Irvine, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 5, 2026, 2:17 AM EDT
Completed Not applicable Interventional Results available

Intermittent Fasting and a No-Sugar Diet for Long COVID Symptoms

NCT06214455
View directory record Official record
Conditions
Long Covid19, Long COVID
Interventions
Low sugar diet and 10-12 hour eating window, Low sugar diet, 8 hour eating window and fasting
Other
Lead sponsor
Pacific Northwest University of Health Sciences
Other
Eligibility
19 Years to 69 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Boulder, Colorado • Yakima, Washington
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 5, 2026, 2:17 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 5, 2026, 2:17 AM EDT
Active, not recruiting Phase 3 Interventional

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

NCT06076642
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
TAK-881, Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US)
Biological · Device
Lead sponsor
Takeda
Industry
Eligibility
2 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
Irvine, California • Walnut Creek, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 5, 2026, 2:17 AM EDT
Recruiting Phase 1 Interventional

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

NCT05714072
View directory record Official record
Conditions
Myelofibrosis Due to and Following Polycythemia Vera
Interventions
Ruxolitinib, Abemaciclib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 5, 2026, 2:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Trial of the Ideal Protein System Versus Low Fat Diet for Weight Loss

NCT03515889
View directory record Official record
Conditions
Weight Loss
Interventions
Ideal Protein Weight Loss Method, Standard Weight Loss
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
22 Years to 79 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bogalusa, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 5, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

NCT04777201
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Faricimab, Sham Procedure, Anti-VEGF Therapy
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
1,036 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
85
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 5, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional Results available

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

NCT02258464
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Background hormonal therapy
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Bakersfield, California • La Jolla, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Sep 5, 2026, 2:17 AM EDT